Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic <i>BRCA2</i> Mutation.

Su, Yu-Li; Ng, Ca Tung; Jan, Yi-Hua; Hsieh, Yi-Lin; Wu, Chia-Ling; Tan, Kien Thiam

Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation.

Su, Yu-Li; Ng, Ca Tung; Jan, Yi-Hua; Hsieh, Yi-Lin; Wu, Chia-Ling; Tan, Kien Thiam.

Afiliação

Su YL; Division of Hematology Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Kaohsiung, Taiwan.
Ng CT; Clinical Trial Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Jan YH; ACT Genomics Co., Ltd, Taipei City, Taiwan.
Hsieh YL; ACT Genomics Co., Ltd, Taipei City, Taiwan.
Wu CL; ACT Genomics Co., Ltd, Taipei City, Taiwan.
Tan KT; ACT Genomics Co., Ltd, Taipei City, Taiwan.

Onco Targets Ther ; 14: 3895-3901, 2021.

Article em En | MEDLINE | ID: mdl-34234458

Palavras-chave

BRCA2 mutation; combined hepatocellular cholangiocarcinoma; comprehensive genomic panel; olaparib; precision oncology

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article